Table 6.
Association of Serum Peroxiredoxin 4 With Incident Cardiovascular Events or CVD Mortality (n=8141)
| HR (95% CI) by Tertiles of Peroxiredoxin 4 (U/L) | |||
|---|---|---|---|
| Model | 1 | 2 | 3 |
| Adjusted for model 2 | 1.00 | 1.03 (0.83 to 1.29) | 1.29 (1.05 to 1.59) |
| Adjusted for model 2+BMI | 1.00 | 1.03 (0.83 to 1.28) | 1.29 (1.05 to 1.59) |
| Adjusted for model 2+waist circumference | 1.00 | 1.03 (0.83 to 1.28) | 1.31 (1.06 to 1.59) |
| Adjusted for model 2+family history of CVD | 1.00 | 1.04 (0.83 to 1.29) | 1.30 (1.06 to 1.60) |
| Adjusted for sex, age, smoking+metabolic syndrome | 1.00 | 1.03 (0.82 to 1.28) | 1.38 (1.12 to 1.76) |
| Adjusted for model 2+insulin | 1.00 | 1.04 (0.83 to 1.30) | 1.31 (1.06 to 1.61) |
| Adjusted for model 2+kidney disease | 1.00 | 1.03 (0.83 to 1.29) | 1.30 (1.05 to 1.60) |
Hazard ratios (HRs) with 95% confidence intervals (95% CIs) have been adjusted for model 2, in which the Framingham risk factors age, sex, smoking, systolic blood pressure, use of antihypertensive therapy, diabetes at baseline, total cholesterol, and HDL cholesterol were included. Kidney disease was defined on the basis of a history of kidney disease requiring dialysis or estimated glomerular filtration rate (eGFR) below 60 mL/min per 1.73 m2. We used the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation to calculate eGFR. BMI indicates body mass index; CVD, cardiovascular disease; and HDL, high-density lipoprotein.